{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:51:41Z","timestamp":1755798701318,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,19]]},"DOI":"10.7759\/cureus.90466","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:24:28Z","timestamp":1755602668000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary Hyperoxaluria Type 2 Masquerading as Chronic Kidney Disease of Unknown Origin in an Adolescent: A Case Report"],"prefix":"10.7759","author":[{"given":"Muskan","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manidipa","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pujan","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lovish","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.32","article-title":"The primary hyperoxalurias","volume":"75","author":"Hoppe B","year":"2009","unstructured":"Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009, 75:1264-71. 10.1038\/ki.2009.32","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat P","year":"2013","unstructured":"Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013, 369:649-58. 10.1056\/NEJMra1301564","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria","volume":"26","author":"Hopp K","year":"2015","unstructured":"Hopp K, Cogal AG, Bergstralh EJ, et al.. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015, 26:2559-70. 10.1681\/ASN.2014070698","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/864580","article-title":"Primary hyperoxaluria","volume":"2011","author":"Harambat J","year":"2011","unstructured":"Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol. 2011, 2011:864580. 10.4061\/2011\/864580","journal-title":"Int J Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp8.3","article-title":"Epidemiology of primary hyperoxaluria type 1","volume":"10","author":"Cochat P","year":"1995","unstructured":"Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N. Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant. 1995, 10:3-7. 10.1093\/ndt\/10.supp8.3","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/18.2.273","article-title":"Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome","volume":"18","author":"van Woerden CS","year":"2003","unstructured":"van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant. 2003, 18:273-9. 10.1093\/ndt\/18.2.273","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.08.018","article-title":"Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up","volume":"96","author":"Garrelfs SF","year":"2019","unstructured":"Garrelfs SF, Rumsby G, Peters-Sengers H, et al.. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 2019, 96:1389-99. 10.1016\/j.kint.2019.08.018","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.7980","article-title":"Association of urinary oxalate excretion with the risk of chronic kidney disease progression","volume":"179","author":"Waikar SS","year":"2019","unstructured":"Waikar SS, Srivastava A, Palsson R, et al.. Association of urinary oxalate excretion with the risk of chronic kidney disease progression. JAMA Intern Med. 2019, 179:542-51. 10.1001\/jamainternmed.2018.7980","journal-title":"JAMA Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00488.2015","article-title":"Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL\/6 mice","volume":"310","author":"Mulay SR","year":"2016","unstructured":"Mulay SR, Eberhard JN, Pfann V, et al.. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL\/6 mice. Am J Physiol Renal Physiol. 2016, 310:F785-95. 10.1152\/ajprenal.00488.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07430711","article-title":"Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy","volume":"7","author":"Harambat J","year":"2012","unstructured":"Harambat J, van Stralen KJ, Espinosa L, et al.. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol. 2012, 7:458-65. 10.2215\/CJN.07430711","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.113","article-title":"An update on primary hyperoxaluria","volume":"8","author":"Hoppe B","year":"2012","unstructured":"Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012, 8:467-75. 10.1038\/nrneph.2012.113","journal-title":"Nat Rev Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.09.022","article-title":"Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives","volume":"5","author":"Devresse A","year":"2020","unstructured":"Devresse A, Cochat P, Godefroid N, Kanaan N. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep. 2020, 5:2136-45. 10.1016\/j.ekir.2020.09.022","journal-title":"Kidney Int Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2741\/1135","article-title":"Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria","volume":"8","author":"Hoppe B","year":"2003","unstructured":"Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci. 2003, 8:e437-43. 10.2741\/1135","journal-title":"Front Biosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050145","article-title":"Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure","volume":"10","author":"Hoppe B","year":"1996","unstructured":"Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, Brodehl J. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol. 1996, 10:488-92. 10.1007\/s004670050145","journal-title":"Pediatr Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(12)80833-x","article-title":"Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria","volume":"19","author":"Marangella M","year":"1992","unstructured":"Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis. 1992, 19:546-53. 10.1016\/s0272-6386(12)80833-x","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.06.021","article-title":"Etiologies, clinical features, and outcome of oxalate nephropathy","volume":"5","author":"Buysschaert B","year":"2020","unstructured":"Buysschaert B, Aydin S, Morelle J, Gillion V, Jadoul M, Demoulin N. Etiologies, clinical features, and outcome of oxalate nephropathy. Kidney Int Rep. 2020, 5:1503-9. 10.1016\/j.ekir.2020.06.021","journal-title":"Kidney Int Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000533295","article-title":"Oxalate nephropathy and the mechanism of oxalate-induced kidney injury","volume":"9","author":"Bao D","year":"2023","unstructured":"Bao D, Wang Y, Zhao MH. Oxalate nephropathy and the mechanism of oxalate-induced kidney injury. Kidney Dis (Basel). 2023, 9:459-68. 10.1159\/000533295","journal-title":"Kidney Dis (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria","volume":"101","author":"Hoppe B","year":"2022","unstructured":"Hoppe B, Koch A, Cochat P, et al.. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2022, 101:626-34. 10.1016\/j.kint.2021.08.015","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs SF","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, et al.. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021, 384:1216-26. 10.1056\/NEJMoa2021712","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.06.011","article-title":"Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy","volume":"97","author":"Wyatt CM","year":"2020","unstructured":"Wyatt CM, Dr\u00fceke TB. Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int. 2020, 97:17-9. 10.1016\/j.kint.2019.06.011","journal-title":"Kidney Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392479-primary-hyperoxaluria-type-2-masquerading-as-chronic-kidney-disease-of-unknown-origin-in-an-adolescent-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:24:29Z","timestamp":1755602669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392479-primary-hyperoxaluria-type-2-masquerading-as-chronic-kidney-disease-of-unknown-origin-in-an-adolescent-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.90466","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}